Using an expanded algorithm to estimate prevalence of amyotrophic lateral sclerosis in U.S. and UK
Authors:
- 25 January 2024
- journal article
- research article
- Published by Springer Nature in Neurological Sciences
- Vol. 45 (5) , 2321-2324
Abstract
Background There is an increasing need to better understand the burden of amyotrophic lateral sclerosis (ALS) using real-world data (RWD). However, identifying ALS cases using RWD presents several challenges due to the rarity of ALS and the differences in database coding systems. Methods MarketScan claims, and the UK Clinical Practice Research Datalink (CPRD) databases were searched for diagnosis codes of ALS or MND, the only drugs approved for treating ALS (riluzole and edaravone) and clinical visits with 12-month enrolment prior to 1 January 2011. The main algorithm required ≥ 1 ALS diagnosis code together with prescriptions or clinical visits. We expanded the existing algorithm to identify unspecific (possible) ALS group that had codes for motor neuron disease (MND) and the ALS drugs. The study period was from 1 January 2011 until 31 December 2020. Results We identified 16,246 patients with ≥ 1 ALS code in Marketscan (denominator n = 85,279,619), yet only 184 were found in the UK CPRD (denominator n = 21,318,589). Using the main algorithm 9,433 ALS patients were included in MarketScan, with a prevalence ranged between 4.5 per 100,000 in 2019 and 6.2 in 2015. In MarketScan, 3,658 (4.3 per 100,000) had ≥ 1 MND code and the ALS drug codes (possible cases). In CPRD, 47.9% of 2,785 patients with ≥ 1 MND code had a prescription for riluzole (6.3 per 100,000), regarded as possible ALS cases. Conclusions The expanded algorithm enabled the identification of a large population with ALS, or possible ALS, and the estimation of ALS prevalence in MarketScan and CPRD.Keywords
Funding Information
- UCB Celltech
This publication has 10 references indexed in Scilit:
- Safety and efficacy of edaravone in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysisNeurological Sciences, 2023
- Amyotrophic lateral sclerosisThe Lancet, 2022
- Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral SclerosisJAMA Neurology, 2022
- Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016The Lancet Neurology, 2019
- Prevalence of Amyotrophic Lateral Sclerosis — United States, 2014MMWR. Morbidity and Mortality Weekly Report, 2018
- Amyotrophic Lateral SclerosisNew England Journal of Medicine, 2017
- Accuracy of routinely-collected healthcare data for identifying motor neurone disease cases: A systematic reviewPLOS ONE, 2017
- Projected increase in amyotrophic lateral sclerosis from 2015 to 2040Nature Communications, 2016
- Feasibility of creating a National ALS Registry using administrative data in the United StatesAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014
- Amyotrophic lateral sclerosis in an urban settingJournal of Neurology, 2006